Anthony J. Polverino
Direktor/Vorstandsmitglied bei BRAINSTORM CELL THERAPEUTICS INC.
Vermögen: 13 811 $ am 30.04.2024
Aktive Positionen von Anthony J. Polverino
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 05.02.2018 | - |
| Independent Dir/Board Member | 05.02.2018 | - |
Karriereverlauf von Anthony J. Polverino
Ehemalige bekannte Positionen von Anthony J. Polverino
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 20.09.2018 | 19.01.2022 |
| KITE PHARMA INC | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 | 01.01.2018 |
| AMGEN INC. | Corporate Officer/Principal | - | - |
Ausbildung von Anthony J. Polverino
| University of Adelaide | Undergraduate Degree |
| Flinders University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Australien | 3 |
| Kanada | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
- Börse
- Insiders
- Anthony J. Polverino
- Erfahrung
